Promising results from the Neuroblastoma Phase II vaccine study at Biotec Pharmacon

Jessica Green

Jessica Green

The ongoing vaccine study with Soluble Beta-Glucan (SBG®) from Biotec Pharmacon (”Biotec”, OSE: BIOTEC) as an oral adjuvant shows very promising treatment effects in children with relapsed high-risk neuroblastoma. The immuno-oncology investigators in New York, interpret a promising adjuvant effect of SBG® on cancer vaccine.

“The results (outlined below) offer further hope for children with Neuroblastoma. Additionally, this vaccine/SBG® treatment regime has an excellent safety profile with no observable side-effects”, states Chief Scientific Officer, Rolf Engstad.